IMS Health data for 2009 creates an interesting picture of global drug sales and growth in specific therapeutic classes. WBC (wbcbaltimore.com) has taken a look and found that the global picture is clearly different when compared to U.S. pharmacy benefit plan sponsor drug spend. In the U.S., antipsychotics were the leading therapeutic class with $14.6 billion in sales. […]
Download Our Whitepaper!
7 Crucial Tips
Here are 7 Crucial Tips you'll want to know to reduce your Drug Spend in your PBM Contract.
